NCI Cancer and Inflammation Program researchers developed multiple novel human anti-HIV-1 domain antibodies and their fusion proteins with two-domain or single-domain human soluble CD4 that can potentially be used alone or synergistically with other anti-HIV-1 antibodies and antiretroviral drugs as therapeutics and/or preventatives for infection by different HIV-1 strains. These are available for co-development and licensing.
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to co-develop, evaluate or commercialize therapeutic compositions and methods for pre-vaccination of organ transplant recipients against BK polyomavirus (BKV) as well as methods for producing a BKV vaccine against all four known BKV serotypes.
The development of an effective HIV vaccine has been an ongoing area of research. The high variability in HIV-1 virus strains has represented a major challenge in successful development. Ideally, an effective candidate vaccine would provide protection against the majority of clades of HIV. Two major hurdles to overcome are immunodominance and sequence diversity. This vaccine utilizes a strategy for overcoming these two issues by identifying the conserved regions of the virus and exploiting them for use in a targeted therapy. NCI seeks licensees and/or research collaborators to commercialize this technology, which has been validated in macaque models.
This technology provides improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the improved processes relate to improved processes for producing viral DNA template.
The Protein Expression Laboratory at the National Cancer Institute in Frederick, MD is seeking statements of capability or interest from parties interested in collaborative research to further develop a platform technology for the targeted intra-cellular delivery of proteins using virus-like particles (VLPs).
The National Cancer Institute’s Vaccine Branch seeks partners interested in collaborative research to continue clinical development and/or license a multi-epitope therapeutic cancer vaccine. The research is in early-stage clinical evaluation, with in vitro and in vivo (animal and human) data available.
Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs) and utilize them to evade immune surveillance and mediate metastasis. tBregs directly inhibit CD4+ and CD8+ T cell activity in a cell contact-dependent manner, induce FoxP3+ T cell activity, and promote Treg-dependent metastasis. The National Institute on Aging's Immunotherapeutics Unit, is seeking parties interested in licensing or co-development of regulatory B cells to control autoimmune diseases and strategies that inactivate tBregs to control cancer immune escape.
Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license or co-develop this technology toward commercialization.
Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Stimulation of T cells with the Brachyury peptide promote a robust immune response and lead to targeted lysis of invasive tumor cells.
Researchers at the NCI have developed a novel treatment for prostate and breast cancer using synthetic peptides derived from TARP, the T cell receptor gamma alternate reading frame protein. These immunogenic peptides from TARP elicit an immune response, triggering T cells to kill only the cancer cells within a patient.
Researchers at the NCI have developed a treatment for prostate and breast cancer using multivalent peptides derived from TARP, the T cell receptor gamma alternate reading frame protein. These immunogenic peptides from TARP elicit an immune response, triggering T cells to kill only the cancer cells within a patient.
Researchers at the NCI have developed synergistic combinations of Toll-like receptors (TLRs) that can be combined with other therapeutics to have an immunostimulatory effect. This induced immune response by these TLRs can satisfy unmet needs for novel adjuvants.
Researchers at the NCI have developed a method of enhancing immune response in patients by using 15 kD granulysin. Granulysin, a proinflammatory molecule, is broadly applicable for the treatment of several diseases.
Researchers at the National Institute on Aging working on cancer immunotherapy and detection report the use of SPANX-B polypeptides in the treatment and identification of cancer. Specific human malignancies targeted for the treatments disclosed include melanoma and lung, colon, renal, ovarian and breast carcinomas. The NIA seeks statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize SPANX-B polypeptides in the treatment and identification of
Researchers at the NCI have developed a T cell receptor that recognizes a majority of human kidney tumors. This TCR is able to kill kidney cancer cells and offers a new therapeutic option for patients.
Researchers at the NCI have developed a method of genetically engineering lymphocytes to expressed elevated levels of cytokine proteins. This technology is useful for improving cellular adoptive immunotherapies to treat a range of infectious diseases and cancers.
Researchers at the NCI have developed a method of lowering a viral load of a virus resistant to antiviral drugs. The inclusion of a synthetic peptide induces a cytotoxic T lymphocyte (CTL) response specific for cells infected with the antiviral drug-resistant virus.
Researchers at the NCI have developed a method of using genetic modifications to generate leukocytes with multiple specificities. This technology represents a potential therapy for a wide variety of malignancies, and because of the genetic modification used, this therapy will be applicable to patients of any MHC type.